ClinicalTrials.gg
TerminatedNCT02656303Updated Jun 22, 2023Results posted

A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304

A Phase 2 interventional study of Ublituximab and Umbralisib in Chronic Lymphocytic Leukemia, sponsored by TG Therapeutics, Inc.. Terminated at 87 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-22.

Sponsored by TG Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Strategic/Business Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
116
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell — none open to participants now, 1 under way, none of them phase 3. ublituximab · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
5th of 13
116 · median 51
Started
2016
the only one that year
Phase 2
5 of 13
none open now
Registered
8th of 13
by date
Lead sponsor
10 of 13
TG Therapeutics, Inc.

Among the 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 5th largest by enrollment, is the only one that started in 2016, is one of 5 in phase 2, and was the 8th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

None of the 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell is open now. The open studies under Leukemia, Lymphocytic, Chronic, B-Cell, anywhere →

About ublituximab

ublituximab: first FDA approval 2022 (BRIUMVI), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell as a file.
02

Study summary

The purpose of this study was to provide the opportunity to the participants who progressed on treatment arm previously in the study UTX-TGR-304 (NCT02612311) to receive ublituximab (TG-1101) treatment in combination with umbralisib (TGR-1202).

03

Conditions studied

  • Chronic Lymphocytic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Prior treatment in clinical trial UTX-TGR-304
  • (ECOG) score of 0 to 2

Exclusion criteria

Exclusion Criteria:

  • Participants to ublituximab + TGR-1202
  • Transformation of chronic lymphocytic leukemia (CLL) to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    Parent Study Arm B

    Participants from Arm B of the parent trial (UTX-TGR-304) received ublituximab, 150 milligrams (mg), intravenously (IV), on Day 1, 750 mg on Day 2, followed by 900 mg on Days 8 and 15 of Cycle 1 (cycle length=28 days), Day 1 of Cycles 2-6, and once every 3 months thereafter, along with umbralisib, 800 mg, orally, once daily during each cycle until disease progression, lack of tolerability, or until the treatment is commercially available or up to 78 months.

    Biological: Ublituximab · Drug: Umbralisib

  • Experimental
    Parent Study Arm C

    Participants from Arm C of the parent trial (UTX-TGR-304) received ublituximab, 900 mg, IV, on Day 1 of Cycles 1-6 (cycle length=28 days), and once every 3 months thereafter, along with umbralisib, 800 mg, orally, once daily during each cycle until disease progression, lack of tolerability, or until the treatment is commercially available or up to 78 months.

    Biological: Ublituximab · Drug: Umbralisib

  • Experimental
    Parent Study Arm D

    Participants from Arm D of the parent trial (UTX-TGR-304) received ublituximab, 150 mg, IV, on Day 1, 750 mg on Day 2, followed by 900 mg on Days 8 and 15 of Cycle 1 (cycle length=28 days), Day 1 of Cycles 2-6, and once every 3 months thereafter, along with umbralisib, 800 mg, orally, once daily during each cycle until disease progression, lack of tolerability, or until the treatment is commercially available or up to 78 months.

    Biological: Ublituximab · Drug: Umbralisib

Interventions

  • BiologicalUblituximab

    Ublituximab IV infusion

    Also known as: TG-1101

  • Umbralisib tablets

    Also known as: TGR-1202

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) as Per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria

    ORR was defined as sum of participants with partial responses (PR) and complete responses (CR). CR: No evidence of new disease; Absolute lymphocyte count(ALC)\<4x10\^9/liter(L); Regression of all target nodal masses to ≤1.5 centimeters (cm) in longest diameter(LD); Normal spleen,liver size; Regression to normal of all nodal non-target disease and disappearance of all detectable; Non-nodal, non-target disease; Morphologically negative bone marrow; No lymphoid nodules; Absolute neutrophil count(ANC)\>1.5x10\^9/L,platelets≥100x10\^9/L,hemoglobin (Hgb)≥110 gram per liter(g/L). PR: No evidence of new disease; Response in 2 of following if abnormal at baseline: ALC\<4x10\^9/L or ≥50% decrease from baseline in sum of products(SPD) of target nodal lesions; splenomegaly; hepatomegaly;≥50% decrease from baseline in CLL marrow infiltrate/B-lymphoid nodules; response in any 1:ANC\>1.5x10\^9/L,platelets\>100x10\^9/L,Hgb\>110g/L or ≥50% increase over baseline in any of these.

    Time frame: Up to 76 months

  2. Complete Response (CR) Rate Per iwCLL Criteria

    The CR rate was defined as the percentage of participants who achieved CR. CR: No evidence of new disease; ALC \<4 x 10\^9/L; Regression of all target nodal masses to normal size ≤1.5 cm in the LD; Normal spleen and liver size; Regression to normal of all nodal non-target disease and disappearance of all detectable; Non-nodal, non-target disease; Morphologically negative bone marrow; No lymphoid nodules; ANC \>1.5 x 10\^9/L, platelets ≥100 x 10\^9/L, Hgb ≥110 g/L.

    Time frame: Up to 76 months

  3. Progression-Free Survival (PFS) Per iwCLL Criteria

    PFS was defined as the interval from enrollment to the earlier of the first documentation of definitive disease progression (PD) or death from any cause. PD was appearance of new nodes \>1.5 cm in the LD and \>1.0 in longest perpendicular diameter (LPD), new or recurrent hepatomegaly or splenomegaly, new or reappearance of an unequivocal extra-nodal lesion, ≥50% increase from the nadir in the sum of products of diameters (SPD) of target lesions, ≥50% increase in the LD of an individual node or extra-nodal mass, splenic/hepatic enlargement of ≥50% from nadir, unequivocal increase in the size of non-target disease, transformation to a more aggressive histology, decrease in platelet count or Hgb, \>50% decrease from the highest on-study platelet count, \>20 g/L decrease from the highest on-study Hgb.

    Time frame: Up to 76 months

  4. Duration of Response (DOR)

    DOR:Interval from first documentation of CR/PR to first documentation of PD or death from any cause.CR:ALC\<4x10\^9/L;Regression to normal of target nodal masses,nodal non-target disease,and no detectable non-nodal,non-target disease;Normal spleen,liver size;Morphologically negative bone marrow,No lymphoid nodules;ANC\>1.5x10\^9/L,Platelets≥100x10\^9/L,Hgb≥110 g/L.PR:Response in 2 or more:ALC\<4x10\^9/L, ≥50% drop from baseline in ALC or SPD of target nodal lesions,Hepatosplenomegaly,≥50% decrease from baseline in CLL marrow infiltrate/B-lymphoid nodules;Response in 1 or more:ANC\>1.5x10\^9/L,Platelets\>100x10\^9/L,Hgb\>110 g/L or ≥50% increase over baseline in any.PD:Response in 1 or more:new nodes,Hepatosplenomegaly,unequivocal extra-nodal lesion;≥50% increase from nadir in SPD of target lesions or LD of node/extra-nodal mass or Splenic/Hepatic size,Unequivocal increase in non-target disease,More aggressive histology;Drop of \>50% in platelets/\>20g/L in Hgb from highest on-study count.

    Time frame: Up to 76 months

Secondary outcomes

  1. Minimal Residual Disease (MRD) Negativity Rate

    MRD negativity rate is defined as the percentage of participants who are MRD negative. If a participant was determined to be MRD negative by peripheral blood, a bone marrow aspirate was obtained to assess MRD in the bone marrow.

    Time frame: From Cycle 6 until Cycle 15 (cycle length=28 days) (Up to approximately 76 months)

  2. Number of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)

    An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product. An AE does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is any AE that occur after first dosing of study medication and through the end of the study or through 30 days after the last dose of study treatment, or is considered treatment-related regardless of the start date of the event, or is present before first dosing of study medication but worsens in intensity or the investigator subsequently considers treatment-related.

    Time frame: Up to 78 months

07

Results

Posted Jun 22, 2023
Limitations and caveats
Due to sponsor's business decision, the clinical trial was terminated by the sponsor.

Participant flow

A total of 116 participants took part across 50 investigative sites in the United States, United Kingdom, Italy, and Poland from 07 January 2016 to 11 July 2022.

Participant flow — Overall Study
MilestoneParent Study Arm BParent Study Arm CParent Study Arm D
Started673118
Completed000
Not completed673118
Withdrew: Adverse event320
Withdrew: Death1241
Withdrew: Lack of efficacy100
Withdrew: Non-compliance with study110
Withdrew: Investigator decision210
Withdrew: Progressive disease251410
Withdrew: Study terminated by sponsor2075
Withdrew: Withdrawal of consent by participants110
Withdrew: Initiation of non-protocol intervention100
Withdrew: Reason not specified112

Outcome measures

PrimaryOverall Response Rate (ORR) as Per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria

ORR was defined as sum of participants with partial responses (PR) and complete responses (CR). CR: No evidence of new disease; Absolute lymphocyte count(ALC)\<4x10\^9/liter(L); Regression of all target nodal masses to ≤1.5 centimeters (cm) in longest diameter(LD); Normal spleen,liver size; Regression to normal of all nodal non-target disease and disappearance of all detectable; Non-nodal, non-target disease; Morphologically negative bone marrow; No lymphoid nodules; Absolute neutrophil count(ANC)\>1.5x10\^9/L,platelets≥100x10\^9/L,hemoglobin (Hgb)≥110 gram per liter(g/L). PR: No evidence of new disease; Response in 2 of following if abnormal at baseline: ALC\<4x10\^9/L or ≥50% decrease from baseline in sum of products(SPD) of target nodal lesions; splenomegaly; hepatomegaly;≥50% decrease from baseline in CLL marrow infiltrate/B-lymphoid nodules; response in any 1:ANC\>1.5x10\^9/L,platelets\>100x10\^9/L,Hgb\>110g/L or ≥50% increase over baseline in any of these.

Time frame:
Up to 76 months

No measurements were reported for this outcome.

PrimaryComplete Response (CR) Rate Per iwCLL Criteria

The CR rate was defined as the percentage of participants who achieved CR. CR: No evidence of new disease; ALC \<4 x 10\^9/L; Regression of all target nodal masses to normal size ≤1.5 cm in the LD; Normal spleen and liver size; Regression to normal of all nodal non-target disease and disappearance of all detectable; Non-nodal, non-target disease; Morphologically negative bone marrow; No lymphoid nodules; ANC \>1.5 x 10\^9/L, platelets ≥100 x 10\^9/L, Hgb ≥110 g/L.

Time frame:
Up to 76 months

No measurements were reported for this outcome.

PrimaryProgression-Free Survival (PFS) Per iwCLL Criteria

PFS was defined as the interval from enrollment to the earlier of the first documentation of definitive disease progression (PD) or death from any cause. PD was appearance of new nodes \>1.5 cm in the LD and \>1.0 in longest perpendicular diameter (LPD), new or recurrent hepatomegaly or splenomegaly, new or reappearance of an unequivocal extra-nodal lesion, ≥50% increase from the nadir in the sum of products of diameters (SPD) of target lesions, ≥50% increase in the LD of an individual node or extra-nodal mass, splenic/hepatic enlargement of ≥50% from nadir, unequivocal increase in the size of non-target disease, transformation to a more aggressive histology, decrease in platelet count or Hgb, \>50% decrease from the highest on-study platelet count, \>20 g/L decrease from the highest on-study Hgb.

Time frame:
Up to 76 months

No measurements were reported for this outcome.

PrimaryDuration of Response (DOR)

DOR:Interval from first documentation of CR/PR to first documentation of PD or death from any cause.CR:ALC\<4x10\^9/L;Regression to normal of target nodal masses,nodal non-target disease,and no detectable non-nodal,non-target disease;Normal spleen,liver size;Morphologically negative bone marrow,No lymphoid nodules;ANC\>1.5x10\^9/L,Platelets≥100x10\^9/L,Hgb≥110 g/L.PR:Response in 2 or more:ALC\<4x10\^9/L, ≥50% drop from baseline in ALC or SPD of target nodal lesions,Hepatosplenomegaly,≥50% decrease from baseline in CLL marrow infiltrate/B-lymphoid nodules;Response in 1 or more:ANC\>1.5x10\^9/L,Platelets\>100x10\^9/L,Hgb\>110 g/L or ≥50% increase over baseline in any.PD:Response in 1 or more:new nodes,Hepatosplenomegaly,unequivocal extra-nodal lesion;≥50% increase from nadir in SPD of target lesions or LD of node/extra-nodal mass or Splenic/Hepatic size,Unequivocal increase in non-target disease,More aggressive histology;Drop of \>50% in platelets/\>20g/L in Hgb from highest on-study count.

Time frame:
Up to 76 months

No measurements were reported for this outcome.

SecondaryMinimal Residual Disease (MRD) Negativity Rate

MRD negativity rate is defined as the percentage of participants who are MRD negative. If a participant was determined to be MRD negative by peripheral blood, a bone marrow aspirate was obtained to assess MRD in the bone marrow.

Time frame:
From Cycle 6 until Cycle 15 (cycle length=28 days) (Up to approximately 76 months)

No measurements were reported for this outcome.

SecondaryNumber of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)

An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product. An AE does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is any AE that occur after first dosing of study medication and through the end of the study or through 30 days after the last dose of study treatment, or is considered treatment-related regardless of the start date of the event, or is present before first dosing of study medication but worsens in intensity or the investigator subsequently considers treatment-related.

Time frame:
Up to 78 months
Reported as:
Count of participants · Participants
Number of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)
ParticipantsParent Study Arm BParent Study Arm CParent Study Arm D
Number of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)663018

Adverse events

Collected over Up to approximately 78 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Parent Study Arm B23/67 (34.3%)36/67 (53.7%)65/67 (97%)
Parent Study Arm C9/31 (29%)13/31 (41.9%)30/31 (96.8%)
Parent Study Arm D7/18 (38.9%)8/18 (44.4%)17/18 (94.4%)
Most frequent serious events
Showing 10 of 53
Most frequent serious events
EventParent Study Arm BParent Study Arm CParent Study Arm D
PneumoniaInfections and infestations8/672/311/18
COVID-19Infections and infestations4/671/312/18
COVID-19 pneumoniaInfections and infestations5/672/312/18
PneumonitisRespiratory, thoracic and mediastinal disorders1/670/312/18
Aspergillus infectionInfections and infestations0/670/311/18
Infusion related reactionInjury, poisoning and procedural complications0/670/311/18
Pleural effusionRespiratory, thoracic and mediastinal disorders1/670/311/18
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/670/311/18
HypertensionVascular disorders0/670/311/18
Febrile neutropeniaBlood and lymphatic system disorders3/670/310/18
Most frequent other events
Showing 10 of 397
Most frequent other events
EventParent Study Arm BParent Study Arm CParent Study Arm D
DiarrhoeaGastrointestinal disorders35/6711/316/18
Infusion related reactionInjury, poisoning and procedural complications15/675/319/18
NauseaGastrointestinal disorders29/6710/315/18
FatigueGeneral disorders23/6712/312/18
NeutropeniaBlood and lymphatic system disorders17/676/316/18
CoughRespiratory, thoracic and mediastinal disorders22/675/313/18
Upper respiratory tract infectionInfections and infestations14/679/314/18
Neutrophil count decreasedInvestigations3/673/315/18
InsomniaPsychiatric disorders16/675/313/18
Alanine aminotransferase increasedInvestigations15/676/313/18

Baseline characteristics

The Safety Population included all participants who were enrolled and received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Parent Study Arm BParent Study Arm CParent Study Arm DTotal
Mean65.6 ± 8.1866.7 ± 9.4165.7 ± 8.7965.9 ± 8.55
Sex: Female, Male
Sex: Female, Male(Participants)Parent Study Arm BParent Study Arm CParent Study Arm DTotal
Female195529
Male48261387
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Parent Study Arm BParent Study Arm CParent Study Arm DTotal
Hispanic or Latino1012
Not Hispanic or Latino663016112
Unknown or Not Reported0112
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Parent Study Arm BParent Study Arm CParent Study Arm DTotal
Race — White653015110
Race — Black or African American2013
Race — Other0022
Race — Not Reported0101
08

Study locations

87 sites
  • TG Therapeutics Investigational Trial Site
    Huntsville, Alabama 35805, United States
  • TG Therapeutics Investigational Trial Site
    Chandler, Arizona 85224, United States
  • TG Therapeutics Investigational Trial Site
    Fayetteville, Arkansas 72703, United States
  • TG Therapeutics Investigational Trial Site
    Duarte, California 91010, United States
  • TG Therapeutics Investigational Trial Site
    Pleasanton, California 94588, United States
  • TG Therapeutics Investigational Trial Site
    San Diego, California 92108, United States
  • TG Therapeutics Investigational Trial Site
    Whittier, California 90603, United States
  • TG Therapeutics Investigational Trial Site
    Aurora, Colorado 80012, United States
  • TG Therapeutics Investigational Trial Site
    Denver, Colorado 80218, United States
  • TG Therapeutics Investigational Trial Site
    Bridgeport, Connecticut 06606, United States
  • TG Therapeutics Investigational Trial Site
    New Haven, Connecticut 06519, United States
  • TG Therapeutics Investigational Trial Site
    Stamford, Connecticut 06904, United States
  • TG Therapeutics Investigational Trial Site
    Newark, Delaware 19713, United States
  • TG Therapeutics Investigational Trial Site
    Boca Raton, Florida 33486, United States
  • TG Therapeutics Investigational Trial Site
    Fort Myers, Florida 33916, United States
  • TG Therapeutics Investigational Trial Site
    Jacksonville, Florida 32204, United States
  • TG Therapeutics Investigational Trial Site
    Jacksonville, Florida 32256, United States
  • TG Therapeutics Investigational Trial Site
    Saint Petersburg, Florida 33705, United States
  • TG Therapeutics Investigational Trial Site
    Tallahassee, Florida 32308, United States
  • TG Therapeutics Investigational Trial Site
    West Palm Beach, Florida 33401, United States
  • TG Therapeutics Investigational Trial Site
    Albany, Georgia 31701, United States
  • TG Therapeutics Investigational Trial Site
    Chicago, Illinois 60612, United States
  • TG Therapeutics Investigational Trial Site
    Peoria, Illinois 61615, United States
  • TG Therapeutics Investigational Trial Site
    Swansea, Illinois 62526, United States
  • TG Therapeutics Investigational Trial Site
    Urbana, Illinois 61801, United States
  • TG Therapeutics Investigational Trial Site
    Fort Wayne, Indiana 46804, United States
  • TG Therapeutics Investigational Trial Site
    Indianapolis, Indiana 46237, United States
  • TG Therapeutics Investigational Trial Site
    Westwood, Kansas 66210, United States
  • TG Therapeutics Investigational Trial Site
    Louisville, Kentucky 40207, United States
  • TG Therapeutics Investigational Trial Site
    Worcester, Massachusetts 01608, United States
  • TG Therapeutics Investigational Trial Site
    Ann Arbor, Michigan 48197, United States
  • TG Therapeutics Investigational Trial Site
    Detroit, Michigan 48202, United States
  • TG Therapeutics Investigational Trial Site
    Jackson, Michigan 49201, United States
  • TG Therapeutics Investigational Trial Site
    Saint Louis Park, Minnesota 55416, United States
  • TG Therapeutics Investigational Trial Site
    Kansas City, Missouri 64132, United States
  • TG Therapeutics Investigational Trial Site
    Lincoln, Nebraska 68510, United States
  • TG Therapeutics Investigational Trial Site
    Lebanon, New Hampshire 03756, United States
  • TG Therapeutics Investigational Trial Site
    Morristown, New Jersey 07932, United States
  • TG Therapeutics Investigational Trial Site
    Glens Falls, New York 12801, United States
  • TG Therapeutics Investigational Trial Site
    Syracuse, New York 13210, United States
  • TG Therapeutics Investigational Trial Site
    Charlotte, North Carolina 28204, United States
  • TG Therapeutics Investigational Trial Site
    Durham, North Carolina 27705, United States
  • TG Therapeutics Investigational Trial Site
    Durham, North Carolina 27710, United States
  • TG Therapeutics Investigational Trial Site
    Hickory, North Carolina 28602, United States
  • TG Therapeutics Investigational Trial Site
    Kinston, North Carolina 28501, United States
  • TG Therapeutics Investigational Trial Site
    Washington, North Carolina 27889, United States
  • TG Therapeutics Investigational Trial Site
    Canton, Ohio 44718, United States
  • TG Therapeutics Investigational Trial Site
    Toledo, Ohio 43623, United States
  • TG Therapeutics Investigational Trial Site
    Portland, Oregon 97227, United States
  • TG Therapeutics Investigational Trial Site
    Portland, Oregon 98684, United States
  • TG Therapeutics Investigational Trial Site
    Springfield, Oregon 97477, United States
  • TG Therapeutics Investigational Trial Site
    Camp Hill, Pennsylvania 17011, United States
  • TG Therapeutics Investigational Trial Site
    Hershey, Pennsylvania 17033, United States
  • TG Therapeutics Investigational Trial Site
    Philadelphia, Pennsylvania 19106, United States
  • TG Therapeutics Investigational Trial Site
    Pittsburgh, Pennsylvania 15224, United States
  • TG Therapeutics Investigational Trial Site
    Pawtucket, Rhode Island 02860, United States
  • TG Therapeutics Investigational Trial Site
    Greenville, South Carolina 29605, United States
  • TG Therapeutics Investigational Trial Site
    Sioux Falls, South Dakota 57105, United States
  • TG Therapeutics Investigational Trial Site
    Chattanooga, Tennessee 37404, United States
  • TG Therapeutics Investigational Trial Site
    Nashville, Tennessee 37203, United States
  • TG Therapeutics Investigational Trial Site
    Fort Worth, Texas 76104, United States
  • TG Therapeutics Investigational Trial Site
    San Antonio, Texas 78240, United States
  • TG Therapeutics Investigational Trial Site
    Ogden, Utah 84405, United States
  • TG Therapeutics Investigational Trial Site
    Blacksburg, Virginia 24060, United States
  • TG Therapeutics Investigational Trial Site
    Charlottesville, Virginia 22908, United States
  • TG Therapeutics Investigational Trial Site
    Fort Belvoir, Virginia 22060, United States
  • TG Therapeutics Investigational Trial Site
    Seattle, Washington 98109, United States
  • TG Therapeutics Investigational Trial Site
    Spokane, Washington 99216, United States
  • TG Therapeutics Investigational Trial Site
    Wauwatosa, Wisconsin 53226, United States
  • TG Therapeutics Investigational Trial Site
    Ferrara, 44020, Italy
  • TG Therapeutics Investigational Trial Site
    Milan, 20132, Italy
  • TG Therapeutics Investigational Trial Site
    Milan, 20141, Italy
  • TG Therapeutics Investigational Trial Site
    Torino, 10126, Italy
  • TG Therapeutics Investigational Trial Site
    Chorzów, 41-500, Poland
  • TG Therapeutics Investigational Trial Site
    Gdynia, 81-519, Poland
  • TG Therapeutics Investigational Trial Site
    Kraków, 30-510, Poland
  • TG Therapeutics Investigational Trial Site
    Lublin, 20-090, Poland
  • TG Therapeutics Investigational Trial Site
    Słupsk, 76-200, Poland
  • TG Therapeutics Investigational Trial Site
    Warszawa, 02-106, Poland
  • TG Therapeutics Investigational Trial Site
    Warszawa, 02-776, Poland
  • TG Therapeutics Investigational Trial Site
    Warszawa, 02-781, Poland
  • TG Therapeutics Investigational Trial Site
    Warszawa, 50-367, Poland
  • TG Therapeutics Investigational Trial Site
    Łódź, 93-513, Poland
  • TG Therapeutics Investigational Trial Site
    London, SW170QT, United Kingdom
  • TG Therapeutics Investigational Trial Site
    Norwich, NR47UY, United Kingdom
  • TG Therapeutics Investigational Trial Site
    Sunderland, SR47TP, United Kingdom
  • TG Therapeutics Investigational Trial Site
    Wolverhampton, WV100QP, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2016 to primary completion in May 2022, 76 months.

Results were first posted in Jun 2023, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2016
First posted
Jan 14, 2016
StartActual
Jan 7, 2016
Primary completionActual
May 26, 2022
CompletionActual
Jul 11, 2022
Results first posted
Jun 22, 2023
Last update
Jun 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02656303
Responsible party
Sponsor
First posted
Jan 14, 2016
Start date
Jan 7, 2016
Primary completion
May 26, 2022
Completion
Jul 11, 2022
Results posted
Jun 22, 2023
Last update
Jun 22, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ublituximab · Umbralisib

Start the discussion